Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 23:12:1030798.
doi: 10.3389/fonc.2022.1030798. eCollection 2022.

The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial

Jijin Wang  1 , Di Huang  1 , Wenjing Yang  1 , Qingxu Song  1 , Yibin Jia  1 , Pengxiang Chen  1 , Yufeng Cheng  1
Affiliations

The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial

Jijin Wang et al. Front Oncol. .

Abstract

Background: As a potent inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway, Apatinib has been used in antitumor treatment for some time. The study aimed to research the therapeutic effects and toxicity of Apatinib in the treatment of advanced non-small cell lung cancer (NSCLC).

Methods: We retrospectively analyzed 128 NSCLC patients treated with Apatinib in Qilu Hospital of Shandong University. Response Evaluation Criteria in Solid Tumors (RECIST) criteria was adopted to evaluate the treatment effect, and Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 was conducted to determine the Adverse Events (AEs). Cox proportional hazard model and Kaplan-Meier function were applied to evaluate the progression-free survival (PFS) and overall survival (OS).

Results: Among 128 NSCLC patients, partial response (PR) were observed in 15 patients, stable disease (SD) in 66 patients and progressive disease (PD) in 47 patients. The objective response rate (ORR) and disease control rate (DCR) accounted for 11.7% and 63.3% respectively. The median PFS (mPFS) and median OS (mOS) were 4.4 months and 17.2 months. Common side effects of Apatinib were hypertension (n=48), proteinuria (n=35), and hand-foot syndrome (HFS) (n=30), all of the side effects were controllable. No significant difference was observed in efficacy and AEs between the higher dose group (Apatinib>500mg/d) and the lower dose group (Apatinib=500mg/d).

Conclusions: The study suggested that Apatinib with a lower dose (=500mg/d) has good efficacy and safety in the treatment of advanced NSCLC after first-line chemotherapy.

Keywords: advanced non-small cell lung cancer; anti-angiogenesis; apatinib; safety; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Short-term efficacy of patients in NSCLC treated with Apatinib. No patient with CR, 15 patients with PR, 66 patients with SD and 47 with PD (A), the proportions were 0, 36.7%, 11.7%, 51.6% respectively (B). The ORR was 11.7% (C) and DCR was 63.3% (D).
Figure 2
Figure 2
PFS (A) and OS (B) of patients in NSCLC treated with Apatinib. The mPFS and mOS were 4.4 months and 17.2 months in NSCLC treated with Apatinib, respectively.
Figure 3
Figure 3
The relationship between ECOG PS and PFS (A), with P-value <0.001. Patients with smoking history have poorer PFS (B), with P-value <0.001. The relationship between No. of metastases and PFS (C), with P-value of 0.012. The relationship between short-term efficacy and PFS (D). No people reached CR, people who reached PR had better PFS results than people who suffered SD and PD, with P-value <0.001.
Figure 4
Figure 4
The relationship between smoking history and OS (A), with P-value of 0.003. The relationship between line of Apatinib and OS (B), with P-value of 0.026.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin (2021) 71(1):7–33. doi: 10.3322/caac.21654 - DOI - PubMed
    1. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc (2019) 94(8):1623–40. doi: 10.1016/j.mayocp.2019.01.013 - DOI - PubMed
    1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature (2018) 553(7689):446–54. doi: 10.1038/nature25183 - DOI - PubMed
    1. Judah Folkman MD. Tumor angiogenesis: Therapeutic implications. New Engl J Med (1971) 12(285):1182–6. doi: 10.1056/NEJM197111182852108 - DOI - PubMed
    1. Apte RS, Chen DS, Ferrara N. Vegf in signaling and disease: Beyond discovery and development. Cell (2019) 176(6):1248–64. doi: 10.1016/j.cell.2019.01.021 - DOI - PMC - PubMed